ClinicalTrials.gg
Status unknownNCT04558021NICLONEXUpdated Oct 12, 2020

A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19

A Phase 3 interventional study of Niclosamide suspension and Placebo in Covid19, sponsored by Imuneks Farma ilac San. Tic. A.S.. Status unknown at 8 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-12.

Sponsored by Imuneks Farma ilac San. Tic. A.S. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 429 studies in COVID-19 with a site in Turkey — 9 open to participants now, 11 under way, 3 of them phase 3. COVID-19 · Turkey.

Planned enrollment
43rd of 178
200 · median 64
Started
2020
with 166 others
Phase 3
18 of 429
3 open now
Registered
74th of 429
by date

Among the 429 studies in COVID-19 with a site in Turkey, this one is the 43rd largest by planned enrollment of the 178 interventional ones that give a count, is one of 167 that started in 2020, is one of 18 in phase 3, and was the 74th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

9 of the 429 studies in COVID-19 with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in COVID-19 with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to investigate the potential antiviral efficacy and safety of a novel formulation of Niclosamide; a well-known antihelmintic agent, together with an established COVID-19 treatment regimen in patients.

The aim of this study is to evaluate the safety and efficacy profile of niclosamide from the test product (Niclosamide 200 mg/10 mL Suspension) in patients treated for the novel coronavirus infectious disease (COVID-19) in a placebo controlled phase III trial. Both treatment groups will receive an established treatment regimen against COVID-19 together with either niclosamide or placebo.

The efficacy and safety of the molecule is well-known and the properties of novel formulation is well-established. The promising in vitro results of niclosamide as an antiviral compound is well documented and make it an ideal candidate as a therapy against SARS-CoV 2 infection. A good safety profile is expected with solid antiviral activity.

Read the detailed description

The study will be performed in accordance with the relevant articles of the Declaration of Helsinki (1964) as revised in Tokyo (1975), Venice (1983), Hong Kong (1989), Somerset West, RSA (1996), Edinburgh (2000), Washington (2002), Tokyo (2004) and Seoul (2008) and Fortaleza (2013).

The medications for the established treatment regimen will be supplied by Ministry of Health to the study sites. The other study medications, Investigational product and placebo, together with relative documentation, will be supplied to clinical sites by the sponsor. Niclosamide 200 mg/10 mL Suspension and placebo will be supplied together with certificates of analysis by the company responsible for manufacturing of the test product(s).The packaging and labelling of niclosamide and placebo will be done according to the GMP and GCP requirements.

All subjects will receive either 200 mg/10 mL niclosamide suspension or 10 mL placebo three times a day for 5 days, together with an established COVID-19 treatment regimen according to the official guidance for COVID-19 Adult Treatment Algorithm of Republic of Turkey Ministry of Health. Dosings will be administered in accordance with the treatment randomization table throughout the treatment duration.

On each drug administration, the identity of the subject will be confirmed by checking the Identity Card. Administration of the study medication will be performed by the investigator(s) and nurse(s) and supervised by a second medical professional to ensure the correctness of drug administration. Also, a monitor may attend during this procedure. The administration of the study medication is to be followed by a mouth check, to be documented in the CRF and certified by the Investigator.

The statistical analysis will be done according to the provisions of ICH Topic E9, Statistical Principles for Clinical Trials (CPMP/ICH/363/96), September 1998.

Statistical analysis will be performed as a valid case analysis including all subjects in which no major protocol deviations occurred and all primary target variables are available for measurement.

If a subject is to be excluded from evaluation, this decision has to be justified in the Final Study Report.

Continuous variables will be expressed as means ± standard deviations (SD) for the normally distributed data or median with interquartile (IQR) for the skewed data. Correspondingly, two-sample independent t-test and Mann-Whitney U test will be used to detect the difference between groups. Categorical variables will be described as number (%) and compared by χ² test or Fisher's exact test as appropriate. Kaplan-Meier method will be used to estimate the cumulative probability of the endpoint. Cox proportional hazards regression model will be conducted to determine the potential risk factors associated with the endpoint. Statistical significance will be defined as p\<α=0.0054 for interim analysis, p\<α=0.0492 for final analysis using O'Brien-Fleming alpha adjustment. All analyses will be done with R project.

The expected percentage of treatment success is 75% in the experimental group and 50% in the control group. The sample size calculation yields that 170 subjects are needed (85 for each group) to achieve 90% power at α=0.05. Considering potential dropouts, the sample size is estimated as 200 subjects (100 subjects for each group). For interim analysis, 100 subjects (50 subjects for each group) will be evaluated.

Before being enrolled to the clinical study, the subject(s) must consent to participate in the study by signing the informed consent form in response to a complete written and verbal explanation of the nature, scope and possible consequences of the clinical study explained in an understandable way for him/her by the physician.

Each subject will give in writing her/his authorization that the study data may be given for review to the responsible Local and National Authorities.

The subject information and informed consent form will be provided in duplicate [one signed version (original 1) will be left at the investigator; the other signed version (original 2) will be forwarded to the subject].

03

Conditions studied

  • Covid19

Keywords

  • Coronavirus
  • Niclosamide Suspension
  • Anti-viral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Being able to understand the study and to give a written
  2. Adult hospitalized patients (aged ≥18) confirmed or suspected for COVID-19 according to the official General Information, Epidemiology and Diagnosis Guidance for COVID-19 (SARS-CoV-2 Infection) published by Republic of Turkey Ministry of Health showing at least one of the symptoms below:

    1. fever, cough, difficulty in breathing, sore throat, headache, muscle or body aches, new loss of taste or smell, diarreha without explanation of any cause than COVID-19 and history of herself/himself or her/his close contact presenting in the high-risk area of the disease within 14 days prior to the onset of symptoms or
    2. at least one of the symptoms of fever, cough, difficulty in breathing, sore throat, headache, muscle or body aches, new loss of taste or smell, diarrhea without explanation of any cause than COVID-19 and close contact with confirmed COVID-19 case within 14 days prior to symptoms or
    3. fever and at least one of the signs and symptoms of the severe acute respiratory infection (cough and difficulty in breathing) and need for hospitalization due to severe acute respiratory infection (SARI) explanation failure of the clinical features other than COVID-19 SARI: The need for hospitalization in a patient with acute respiratory infection due to fever, cough and dyspnea, tachypnea, hypoxemia, hypotension, wide radiological findings and consciousness developing in the last 14 days.

      or

    4. at least two of the signs and symptoms of fever, cough, difficulty in breathing, sore throat, headache, muscle or body aches, new loss of taste or smell, diarrhoea without explanation of any cause than COVID-19 or
  3. Patients detected with SARS-COV-2 by molecular methods who meet the criteria for possible case of SARS-COV-2

Exclusion criteria

Exclusion Criteria:

  1. Who have allergy to niclosamide and/or any of the treatment agents and/or any of the of the products,
  2. Who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia),
  3. Whose National Early Warning Score 2 (NEWS2) score is indicated as "urgent" or "emergency",
  4. Any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic ,
  5. Who have Multiple Sclerosis,
  6. Who have electrolyte imbalance, chronic haemodialysis or \< 30 30 mL/min/1.73m2,
  7. Who have history of serious cardiovascular diseases,
  8. Who are diagnosed with another ongoing viral infection other than SARS CoV-2,
  9. Who have macrophage activation syndrome,
  10. Who have a need for coagulopathy treatment,
  11. Who have severe liver disease,
  12. Who is pregnant or nursing,
  13. Who are not suitable to 1st articles of inclusion criteria,
  14. Who is not eligible to swallow oral medications,
  15. Who use vitamin C as supplementary medication during the study,
  16. Who are included in another trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intervention Arm-I

    Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health

    Drug: Niclosamide suspension

  • Placebo comparator
    Intervention Arm-II

    10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Physician's judgment on clinical recovery from the time of admission

    The physician will check for the following symptoms: * Fever: axillary temperature ≤36.6°C or oral temperature ≤37.2 °C; * Respiratory rate: ≤24/minute on room air; * Oxygen saturation: \>94% on room air; * Cough: mild or absent on a patient reported scale of severe, moderate, mild, absent.)

    Time frame: Day 1 to day 19

Secondary outcomes

  1. Clinical improvement in NEWS2

    (National Early Warning Score 2) to 0 to 3 (Improvement in fever, respiratory rate, oxygen saturation,alleviation of cough scores to 3 points to 0 in 72 hours)

    Time frame: 3 days from admission

  2. Improvement in serum biomarkers

    An elevated D-dimer,ferritin, thrombocyte, PT, aPTT, troponine and fibrinogen were associated with a poor outcome in COVID19. These parameters will be checked on day 1 and day 3.

    Time frame: Day 1 to day 3

  3. Requirement for indotracheal intubation

    Requirement for indotracheal intubation is a key outcome for unsuccesful treatment

    Time frame: Day 1 to day 19

  4. Occurrence of Macrophage Activation Syndrome(MAS)

    Occurrence of Macrophage Activation Syndrome(MAS) will alert the physician that the patients condition is worsening.

    Time frame: Day 1 to day 19

  5. Occurrence of Coagulopathy

    Occurrence of Coagulopathy will alert the physician that the patients condition is worsening.

    Time frame: Day 1 to day 19

Other outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    The assessment of safety will be based on CTCAE v4.0

    Time frame: Day 1 to day 19

07

Study locations

8 of 8 sites recruiting
  • Akdeniz Üniversitesi Tıp Fakültesi Hastanesi
    Antalya, 07070, Turkey
    Recruiting
  • Antalya Eğitim ve Araştırma Hastanesi
    Antalya, 07100, Turkey
    Recruiting
  • Gaziantep Üniversitesi Tıp Fakültesi Hastanesi
    Gaziantep, 27410, Turkey
    Recruiting
  • Gaziosmanpaşa Taksim Eğitim ve Araştırma Hastanesi
    Istanbul, 34255, Turkey
    Recruiting
  • Dokuz Eylül Üniversitesi Hastanesi
    İzmir, 1606, Turkey
    Recruiting
  • İzmir SBÜ Tepecik Eğitim ve Araştırma Hastanesi
    İzmir, 35020, Turkey
    Recruiting
  • SBÜ Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi
    İzmir, 35110, Turkey
    Recruiting
  • İzmir Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi
    İzmir, 35150, Turkey
    Recruiting
08

References and documents

Publications

  • Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang DR, Liu HW, Liu CY, Huang HW, Chen SC, Hong CF, Lin RK, Chao YS, Hsu JT. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. doi: 10.1128/AAC.48.7.2693-2696.2004. PubMed 15215127 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Jan 2021, 3 months after the start.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 3 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Sep 22, 2020
StartActual
Oct 8, 2020
Primary completionEst.
Jan 30, 2021
CompletionEst.
Feb 14, 2021
Last update
Oct 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04558021
Lead sponsor
Imuneks Farma ilac San. Tic. A.S.
Responsible party
Sponsor
First posted
Sep 22, 2020
Start date
Oct 8, 2020
Primary completion
Jan 30, 2021 (estimated)
Completion
Feb 14, 2021 (estimated)
Last update
Oct 12, 2020

Study contacts

Aydin Erenmemisoglu, Prof.Dr.
Contact
erenmemis@gmail.com
+90 352 224-2322
Ayşe Ö Mete, Dr.
Contact
ayseozlem_ornek@hotmail.com
+90 506 488-3309
Aydin Erenmemisoglu, Prof.Dr.
study director · ALPAN Farma Ltd.Sti.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niclosamide

Start the discussion